Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
BTIG analyst Thomas Shrader reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $9 price target.
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $8 pr...
Maxim Group analyst Jason McCarthy maintains Gain Therapeutics (NASDAQ:GANX) with a Buy and raises the price target from $5 ...
Improvement observed in MDS-UPDRS scores in first 9 participants enrolled; 90-day follow-up continuing in remaining participant...
Extension of the Phase 1b study will allow participants to continue dosing with GT-02287 for an additional nine months after co...
BTIG analyst Thomas Shrader reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $9 price target.
Roth Capital analyst Boobalan Pachaiyappan maintains Gain Therapeutics (NASDAQ:GANX) with a Buy and lowers the price target ...
